Core Points - The executive director of CSPC Pharmaceutical Group, Pan Weidong, was fined 5 million RMB for insider trading related to a failed acquisition deal [1][2] - The insider trading incident involved the purchase of shares in CSPC Innovation Pharmaceutical Co., which was led by Pan Weidong prior to the public announcement of the acquisition [1][2] Summary by Sections Insider Trading Incident - Pan Weidong was found to have knowledge of insider information regarding a restructuring transaction before it was made public, specifically before December 5, 2023 [1][2] - He used the securities account of CSPC's subsidiary, Enbipu, to buy 2.74258 million shares of CSPC Innovation from December 8 to December 20, 2023, totaling approximately 99.99 million RMB [1] Regulatory Actions - The China Securities Regulatory Commission (CSRC) deemed Pan Weidong's actions as insider trading and imposed a fine of 5 million RMB [2] - Pan Weidong has the right to apply for administrative reconsideration or file an administrative lawsuit against the CSRC's decision [2] Impact on Company Operations - The restructuring transaction that Pan Weidong was involved in has been terminated and was not completed as of April 2025 [2] - CSPC Pharmaceutical Group stated that its business operations remain normal and that the penalty is not expected to negatively impact the overall business [2]
石药集团执行董事潘卫东内幕交易被罚500万